Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
- Written by PR Newswire
![]() |
BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)". The Harmonic™ study is being conducted to determine...














